CoronaVac induces lower neutralising activity against variants of concern than natural infection.
作者信息
Vacharathit Vimvara, Aiewsakun Pakorn, Manopwisedjaroen Suwimon, Srisaowakarn Chanya, Laopanupong Thanida, Ludowyke Natali, Phuphuakrat Angsana, Setthaudom Chavachol, Ekronarongchai Supanuch, Srichatrapimuk Sirawat, Wongsirisin Pattama, Sangrajrang Suleeporn, Imsuwansri Thanarath, Kirdlarp Suppachok, Nualkaew Sureeporn, Sensorn Insee, Sawaengdee Waritta, Wichukchinda Nuanjun, Sungkanuparph Somnuek, Chantratita Wasun, Kunakorn Mongkol, Rojanamatin Jinda, Hongeng Suradej, Thitithanyanont Arunee
机构信息
Department of Microbiology, Faculty of Science, Mahidol University, Ratchathewi, Bangkok 10400, Thailand.
Department of Microbiology, Faculty of Science, Mahidol University, Ratchathewi, Bangkok 10400, Thailand; Pornchai Matangkasombut Center for Microbial Genomics, Faculty of Science, Mahidol University, Ratchathewi, Bangkok 10400, Thailand.
出版信息
Lancet Infect Dis. 2021 Oct;21(10):1352-1354. doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26.
Abstract
摘要
相似文献
1
CoronaVac induces lower neutralising activity against variants of concern than natural infection.与自然感染相比，科兴新冠疫苗对变异株的中和活性较低。
Lancet Infect Dis. 2021 Oct;21(10):1352-1354. doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26.
2
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.科兴新冠疫苗诱导产生的针对新冠病毒变异株的血清中和活性。
Lancet Infect Dis. 2021 Aug;21(8):1071-1072. doi: 10.1016/S1473-3099(21)00287-5. Epub 2021 May 27.
3
Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma.严重急性呼吸综合征冠状病毒2型奥密克戎变种对康复期及科兴疫苗血浆的抗性。
Emerg Microbes Infect. 2022 Dec;11(1):424-427. doi: 10.1080/22221751.2022.2027219.
4
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.评估针对 SARS-CoV-2 的 IgG 和中和抗体的免疫原性检测方法的稳健验证和性能比较。
PLoS One. 2022 Feb 7;17(2):e0262922. doi: 10.1371/journal.pone.0262922. eCollection 2022.
5
Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.新冠病毒感染后6个月内肾移植受者体内抗新冠病毒抗体的下降与丧失
Kidney Int. 2021 Feb;99(2):486-488. doi: 10.1016/j.kint.2020.12.001.
6
The long road.漫长的道路。
Science. 2021 Feb 19;371(6531):768-772. doi: 10.1126/science.371.6531.768.
7
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).由SARS-CoV-2 501Y.V2（B.1.351）引发的交叉反应性中和抗体反应
N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.
8
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.接种灭活 SARS-CoV-2 疫苗后突破性病例的免疫特征和临床结局。
Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021.
9
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.既往自然感染人群中新型冠状病毒2型（SARS-CoV-2）的抗体反应
N Engl J Med. 2021 Jul 1;385(1):90-92. doi: 10.1056/NEJMc2103825. Epub 2021 Apr 14.
10
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
引用本文的文献
1
COVID-19 vaccines: current and future challenges.新冠疫苗：当前及未来的挑战
Front Pharmacol. 2024 Nov 6;15:1434181. doi: 10.3389/fphar.2024.1434181. eCollection 2024.
2
Monitoring of adaptive immune responses in healthcare workers who received a Coronavirus disease 2019 vaccine booster dose.对接受2019冠状病毒病疫苗加强针的医护人员适应性免疫反应的监测。
Health Sci Rep. 2024 Jul 16;7(7):e2250. doi: 10.1002/hsr2.2250. eCollection 2024 Jul.
3
Infection kinetics, syncytia formation, and inflammatory biomarkers as predictive indicators for the pathogenicity of SARS-CoV-2 Variants of Concern in Calu-3 cells.在 Calu-3 细胞中，感染动力学、合胞体形成和炎症生物标志物可作为 SARS-CoV-2 关注变体致病性的预测指标。
PLoS One. 2024 Apr 3;19(4):e0301330. doi: 10.1371/journal.pone.0301330. eCollection 2024.
4
Spatiotemporal evolution of SARS-CoV-2 in the Bangkok metropolitan region, Thailand, 2020-2022: implications for future outbreak preparedness.2020-2022 年泰国曼谷大都市区 SARS-CoV-2 的时空演变：对未来疫情爆发准备的启示。
Microb Genom. 2023 Dec;9(12). doi: 10.1099/mgen.0.001170.
5
Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand.泰国清迈自然感染严重急性呼吸综合征冠状病毒2或接种科兴疫苗或ChAdOx1（AZD1222）疫苗后的抗体反应比较。
Vaccine X. 2023 Aug;14:100305. doi: 10.1016/j.jvacx.2023.100305. Epub 2023 Apr 20.
6
Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals.在科兴疫苗初免的老年个体中，接种ChAdOx-1或BNT162b2加强针后针对新冠病毒奥密克戎及其他变体的中和抗体水平和持久性。
Heliyon. 2023 Apr;9(4):e15653. doi: 10.1016/j.heliyon.2023.e15653. Epub 2023 Apr 20.
7
Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice.编码分泌型非稳定 Spike 的 SARS-CoV-2 mRNA 疫苗在雌性小鼠中的免疫原性和保护效力。
Nat Commun. 2023 Apr 21;14(1):2309. doi: 10.1038/s41467-023-37795-0.
8
Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVac® Vaccine and Natural Infection- Induced Antibodies.CoronaVac® 疫苗和自然感染诱导的抗体对野生型和 Alpha SARS-CoV-2 变异株的中和作用。
Curr Microbiol. 2023 Apr 1;80(5):162. doi: 10.1007/s00284-023-03248-6.
9
Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine.在接种两剂灭活或病毒载体新冠疫苗后接种mRNA-1273新冠疫苗第三剂加强针的免疫原性和安全性
Vaccines (Basel). 2023 Feb 27;11(3):553. doi: 10.3390/vaccines11030553.
10
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗开发策略在 SARS-CoV-2 中的应用。
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.
本文引用的文献
1
Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada.评估新型 SARS-CoV-2 变种的相对毒力：加拿大安大略省的回顾性队列研究。
CMAJ. 2021 Oct 25;193(42):E1619-E1625. doi: 10.1503/cmaj.211248. Epub 2021 Oct 4.
2
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.智利开展的灭活 SARS-CoV-2 疫苗有效性研究
N Engl J Med. 2021 Sep 2;385(10):875-884. doi: 10.1056/NEJMoa2107715. Epub 2021 Jul 7.
3
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
4
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.循环中的新冠病毒变异株的中和敏感性。
N Engl J Med. 2021 Jun 17;384(24):2354-2356. doi: 10.1056/NEJMc2103022. Epub 2021 Apr 6.
5
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
Zotero 插件